• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Typhoid Fever - Pipeline Review, H2 2012 Product Image

Typhoid Fever - Pipeline Review, H2 2012

  • Published: September 2012
  • 41 pages
  • Global Markets Direct

Typhoid Fever – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Typhoid Fever - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Typhoid Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Typhoid Fever. Typhoid Fever - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Typhoid Fever.
- A review of the Typhoid Fever products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Typhoid Fever Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Typhoid Fever 7
Typhoid Fever Therapeutics under Development by Companies 9
Typhoid Fever Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Typhoid Fever Therapeutics – Products under Development by Companies 15
Typhoid Fever Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Typhoid Fever Therapeutics Development 17
Emergent BioSolutions Inc. 17
Nanotherapeutics, Inc. 18
Novartis AG 19
Bharat Biotech International Limited 20
Typhoid Fever – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
GelVac - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Salmonella Typhi Vi O-acetyl Pectin-rEPA Conjugate Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Vi-rEPA(2) Conjugate Vaccine + DTP Vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Typhella - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Vi-CRM197 Glycoconjugated Vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
FB-1811 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Typbar - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Vi-CRM197 PCMV - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Typhoid Fever Therapeutics – Drug Profile Updates 36
Typhoid Fever Therapeutics - Dormant Products 37
Typhoid Fever – Product Development Milestones 38
Featured News & Press Releases 38
Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate 38
Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine 38
Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine 39
Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Typhoid Fever, H2 2012 7
Products under Development for Typhoid Fever – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Emergent BioSolutions Inc., H2 2012 17
Nanotherapeutics, Inc., H2 2012 18
Novartis AG, H2 2012 19
Bharat Biotech International Limited, H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Typhoid Fever Therapeutics – Drug Profile Updates 36
Typhoid Fever Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Typhoid Fever, H2 2012 7
Products under Development for Typhoid Fever – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Discovery and Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos